Facebook
Twitter
LinkedIn
Forward
Global Advancements in Bladder Cancer (2023) - English
Complimentary CME Virtual Course!
June 15, 2023 | Time: 7:00-8:30 PM EST
Global Advancements in Bladder Cancer (2023) is an exciting new global educational initiative featuring a series of three interactive, case-based, live virtual courses conducted in English, Spanish and Portuguese. For each session, a Moderator will engage three other subject matter experts in an interactive, interview-style presentation and discussion.
Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed.
Each activity will be recorded and feature subject matter experts from around the world. The webcasts will be made available on AUAUniversity and AUA’s YouTube channel for on‐demand viewing for up to one year. Additionally, the audio of the virtual course presented in English will be released as an episode on AUA’s very popular podcast.
Acknowledgements:
This educational series is supported by an independent educational grant from AstraZeneca.
Target Audience
- Urologists
- Residents
Learning Objectives
After participating in this educational series, participants will be able to:
- Delineate key factors to risk stratify patients with NMIBC and muscle invasive bladder cancer.
- Review guidelines focused on first‐ and second‐line therapies for NMIBC and muscle invasive bladder cancer.
- Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for muscle invasive bladder cancer.
- Identify side effects and possible interventions to ameliorate side effects for these therapies.
- Recognize the urologist’s role in clinical trials and how to overcome obstacles to clinical trial enrollment.
Welcome and Introductions
Pre-Test Questions
Key factors to risk stratify patients with NMIBC and MIBC
Guidelines focused on 1st and 2nd line therapies for NMIBC and MIBC
BCG shortage and patients with BCG unresponsive disease
Emerging treatment options with intravesical and systemic therapies for patients
Side effects and possible interventions to ameliorate side effects for these therapies
Timing and use of neoadjuvant and adjuvant systemic therapy for MIBC
Urologist’s role in clinical trials and overcoming obstacles to enrollment
Post-test Questions
Q&A Session
Global Advancements in Bladder Cancer (2023) - English will be held virtually on Wednesday, June 16, 2023 at 7:00 p.m. - 8:30 p.m. EST.
***Instructions***
- Click on the TAKE COURSE button.
- Click “Start” under "Live Virtual Course" in the Course Progress pane.
- Click on the link provided to register in advance for this webinar.
- After registering, you will receive a confirmation email containing information about joining the webinar.
Faculty Disclosures
| Name | Company Name | Relationship Type | End Date |
| Kates, Max | Fergene | Consultant or Advisor | Current |
| Kates, Max | Merck | Consultant or Advisor | Current |
| Kates, Max | Pfizer | Consultant or Advisor | Current |
| Kates, Max | Photocure | Consultant or Advisor | Current |
| Kates, Max | Seagen/Astellas | Consultant or Advisor | Current |
| Lee, Cheryl Taylore | Merck | Consultant or Advisor | 12/05/2021 |
| Schmidt, Bogdana | None | ||
| Sundi, Debasish | Arquer | Consultant or Advisor | 02/25/2022 |
| Sundi, Debasish | UroGen | Consultant or Advisor | Current |
| Sundi, Debasish | Janssen | Consultant or Advisor | 12/29/2021 |
Education Council Disclosures
COI Review Work Group Disclosures
COI Review Work Group Disclosures
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
Registration for this Live Virtual Course is complimentary.
To join the live course:
- Click on the TAKE COURSE button.
- Click “Live Virtual Course” in the Course Progress pane.
- Click the link to register in advance.
- After registering, you will receive a confirmation email containing information about joining the webinar.
Attendee Information & Policies
AUA Anti-Harassment Policy
AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.
Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly.
The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).
Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.